There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

PASADENA, CA, USA I February 25, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...

Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according ...

A target trial emulation study compared risk for depression among older adults with type 2 diabetes initiating treatment with ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...